These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36469171)

  • 1. Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic.
    Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Iizuka T; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Waragai Y; Kambe T; Kanzaki N; Azuma T; Okamoto H; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Abe W; Tsukada Y; Lee T; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Hamaguchi S; Iseki K
    Clin Exp Med; 2023 Oct; 23(6):2715-2723. PubMed ID: 36469171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
    Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K
    Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis.
    Najjar-Debbiny R; Gronich N; Weber G; Khoury J; Amar M; Stein N; Goldstein LH; Saliba W
    Clin Infect Dis; 2023 Feb; 76(3):453-460. PubMed ID: 36130189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.
    Zheng B; Green ACA; Tazare J; Curtis HJ; Fisher L; Nab L; Schultze A; Mahalingasivam V; Parker EPK; Hulme WJ; Bacon SCJ; DeVito NJ; Bates C; Evans D; Inglesby P; Drysdale H; Davy S; Cockburn J; Morton CE; Hickman G; Ward T; Smith RM; Parry J; Hester F; Harper S; Mehrkar A; Eggo RM; Walker AJ; Evans SJW; Douglas IJ; MacKenna B; Goldacre B; Tomlinson LA
    BMJ; 2022 Nov; 379():e071932. PubMed ID: 36384890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis.
    Huang C; Lu TL; Lin L
    Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance.
    Flisiak R; Zarębska-Michaluk D; Rogalska M; Kryńska JA; Kowalska J; Dutkiewicz E; Dobrowolska K; Jaroszewicz J; Moniuszko-Malinowska A; Rorat M; Podlasin R; Tronina O; Rzymski P
    Pharmacol Rep; 2022 Dec; 74(6):1279-1285. PubMed ID: 36001284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.
    Xie Y; Bowe B; Al-Aly Z
    BMJ; 2023 Mar; 380():e072705. PubMed ID: 36882199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant.
    Butt AA; Dargham SR; Loka S; Shaik RM; Chemaitelly H; Tang P; Hasan MR; Coyle PV; Yassine HM; Al-Khatib HA; Smatti MK; Kaleeckal AH; Latif AN; Zaqout A; Almaslamani MA; Al Khal A; Bertollini R; Abou-Samra AB; Abu-Raddad LJ
    Clin Infect Dis; 2022 Aug; 75(1):e361-e367. PubMed ID: 35404391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial.
    Zou R; Peng L; Shu D; Zhao L; Lan J; Tan G; Peng J; Yang X; Liu M; Zhang C; Yuan J; Wang H; Li S; Lu H; Zhong W; Liu Y
    Front Pharmacol; 2022; 13():939573. PubMed ID: 35784723
    [No Abstract]   [Full Text] [Related]  

  • 16. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Khoo SH; FitzGerald R; Saunders G; Middleton C; Ahmad S; Edwards CJ; Hadjiyiannakis D; Walker L; Lyon R; Shaw V; Mozgunov P; Periselneris J; Woods C; Bullock K; Hale C; Reynolds H; Downs N; Ewings S; Buadi A; Cameron D; Edwards T; Knox E; Donovan-Banfield I; Greenhalf W; Chiong J; Lavelle-Langham L; Jacobs M; Northey J; Painter W; Holman W; Lalloo DG; Tetlow M; Hiscox JA; Jaki T; Fletcher T; Griffiths G;
    Lancet Infect Dis; 2023 Feb; 23(2):183-195. PubMed ID: 36272432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
    Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
    Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
    N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological characteristics of 17 imported patients infected with SARS-CoV-2 Omicron variant.
    Liu X; Chen M; Zhou Z; Chen D; Mo J; Liu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):344-351. PubMed ID: 35545327
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.